Alnylam Files for Initial Public Offering | GenomeWeb

Alnylam Files for Initial Public Offering

Mar 01, 2004

NEW YORK, March 1 (GenomeWeb News) - Alnylam Pharmaceuticals has filed a statement with the SEC for an initial public offering, the company said Friday evening.

The number of shares of common stock Alnylam plans to offer, and their price, have yet to be determined. Bank of America Securities serves as the company's book-runner and lead manager.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Threats of Synthetic Biology

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

Deletion Is Hard to Do

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

So Just How Many Are There?

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

This Week in Genome Research

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.